Literature DB >> 27810043

Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.

Tom F Brouwer1, Dilek Yilmaz2, Robert Lindeboom3, Maurits S Buiten2, Louise R A Olde Nordkamp4, Martin J Schalij2, Arthur A Wilde4, Lieselot van Erven2, Reinoud E Knops4.   

Abstract

BACKGROUND: Transvenous implantable cardioverter-defibrillators (TV-ICDs) improve survival in patients at risk for sudden cardiac death, but complications remain an important drawback. The subcutaneous ICD (S-ICD) was developed to overcome lead-related complications. Comparison of clinical outcomes of both device types in previous studies was hampered by dissimilar patient characteristics.
OBJECTIVES: This retrospective study compares long-term clinical outcomes of S-ICD and TV-ICD therapy in a propensity-matched cohort.
METHODS: The authors analyzed 1,160 patients who underwent S-ICD or TV-ICD implantation in 2 high-volume hospitals in the Netherlands. Propensity matching for 16 baseline characteristics, including diagnosis, yielded 140 matched pairs. Clinical outcomes were device-related complications requiring surgical intervention, appropriate and inappropriate ICD therapy, and were reported as 5-year Kaplan-Meier rate estimates.
RESULTS: All 16 baseline characteristics were balanced in the matched cohort of 140 patients with S-ICDs and 140 patients with TV-ICDs (median age 41 years [interquartile range: 30 to 52 years] and 40% women). The complication rate was 13.7% in the S-ICD group versus 18.0% in the TV-ICD group (p = 0.80). The infection rate was 4.1% versus 3.6% in the TV-ICD groups (p = 0.36). Lead complications were lower in the S-ICD arm compared with the TV-ICD arm, 0.8% versus 11.5%, respectively (p = 0.03). S-ICD patients had more nonlead-related complications than TV-ICD patients, 9.9% versus 2.2%, respectively (p = 0.047). Appropriate ICD intervention (antitachycardia pacing and shocks) occurred more often in the TV-ICD group (hazard ratio [HR]: 2.42; p = 0.01). The incidence of appropriate (TV-ICD HR: 1.46; p = 0.36) and inappropriate shocks (TV-ICD HR: 0.85; p = 0.64) was similar.
CONCLUSIONS: The complication rate in patients implanted with an S-ICD or TV-ICD was similar, but their nature differed. The S-ICD reduced lead-related complications significantly, at the cost of nonlead-related complications. Rates of appropriate and inappropriate shocks were similar between the 2 groups.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  complications; implantable cardioverter-defibrillator; shocks; subcutaneous implantable cardioverter-defibrillator; survival; transvenous implantable cardioverter-defibrillator

Mesh:

Year:  2016        PMID: 27810043     DOI: 10.1016/j.jacc.2016.08.044

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  39 in total

Review 1.  The Changing Epidemiology of Infective Endocarditis in the Twenty-First Century.

Authors:  J Ambrosioni; M Hernandez-Meneses; A Téllez; J Pericàs; C Falces; J M Tolosana; B Vidal; M Almela; E Quintana; J Llopis; A Moreno; José M Miro
Journal:  Curr Infect Dis Rep       Date:  2017-05       Impact factor: 3.725

Review 2.  Comparing the safety of subcutaneous versus transvenous ICDs: a meta-analysis.

Authors:  Li Su; Jia Guo; Yingqun Hao; Hong Tan
Journal:  J Interv Card Electrophysiol       Date:  2021-01-11       Impact factor: 1.900

3.  Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE.

Authors:  Emily P Zeitler; Daniel J Friedman; Zak Loring; Kristen B Campbell; Sarah A Goldstein; Zachary K Wegermann; Jane Schutz; Nicole Smith; Eric Black-Maier; Sana M Al-Khatib; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2019-09-24       Impact factor: 6.343

Review 4.  [Management of inappropriate shocks/T-wave-oversensing in S-ICD®-patients].

Authors:  Robert Larbig; Markus Bettin; Lukas J Motloch; Alicia Fischer; Niklas Bode; Gerrit Frommeyer; Florian Reinke; Andreas Loeher; Lars Eckardt; Julia Köbe
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-02-12

Review 5.  [Journey of the S‑ICD to first-line therapy].

Authors:  Elif Kaya; Reza Wakili; Tienush Rassaf
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

6.  The Risk for Sudden Cardiac Death Among Patients Living With Heart Failure and Human Immunodeficiency Virus.

Authors:  Raza M Alvi; Anne M Neilan; Noor Tariq; Malek O Hassan; Magid Awadalla; Lili Zhang; Maryam Afshar; Adam Rokicki; Connor P Mulligan; Virginia A Triant; Markella V Zanni; Tomas G Neilan
Journal:  JACC Heart Fail       Date:  2019-08-07       Impact factor: 12.035

7.  ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy.

Authors:  Amar Trivedi; Bradley P Knight
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

8.  Ventricular fibrillation survivor due to painless multiple spasm including left main trunk: is the subcutaneous implantable cardioverter-defibrillator necessary?

Authors:  Shozo Sueda; Kaori Fujimoto; Yasuhiro Sasaki; Kazuhisa Nishimura
Journal:  J Cardiol Cases       Date:  2019-07-08

9.  Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.

Authors:  Babak Nazer; Zack Dale; Gianmarco Carrassa; Nosheen Reza; Tuna Ustunkaya; Nikolaos Papoutsidakis; Andrew Gray; Stacey J Howell; Miriam R Elman; Paolo Pieragnoli; Giuseppe Ricciardi; Daniel Jacoby; David S Frankel; Anjali Owens; Iacopo Olivotto; Stephen B Heitner
Journal:  Heart Rhythm       Date:  2020-02-18       Impact factor: 6.343

Review 10.  [Subcutaneous implantable cardioverter-defibrillator : Current status and perspectives].

Authors:  Philipp Niehues; Gerrit Frommeyer; Florian Reinke; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.